Finkelstein Thompson LLP Investigates Potentially Unfair Buyout Of IGate Corp.

The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of iGate Corp. (Nasdaq: IGTE), concerning the Company's proposed acquisition by Cap Gemini S.A. (PAR: CAP.PA). Under the terms of the proposal, iGate shareholders will receive $48.00 in cash for each share of iGate common stock they own. At least one analyst has set a high target price of $55.00 for iGate shares. The entire transaction is valued at approximately $4.0 billion.

The investigation is focused on whether iGate's Board of Directors breached its fiduciary duty in failing to maximize consideration to shareholders, the potential unfairness of the consideration to shareholders, the process by which the Board of Directors considered the transaction, and potential conflicts of interest among the iGates' Board of Directors' members.

If you are interested in discussing your rights as an iGate shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or (202) 337-8000, or by email at  contact@finkelsteinthompson.com.

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our website at  www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010

If you liked this article you might like

IGate (IGTE) Marked As A Barbarian At The Gate

IGate (IGTE) Showing Signs Of Being Strong And Under The Radar

European Stocks Edge Up From 3-Month Lows; Bayer Sells Diabetes Division

Water-Logged And Getting Wetter Stock Of The Day: IGate (IGTE)

Nasdaq Backs Off Record High as Biotech Drags Markets Lower